Literature DB >> 1203879

Survival and phase sensitivity of HeLa cells treated with dianhydrogalactitol (NSC-132313).

I Pályi.   

Abstract

The effect of dianhydrogalactitol on survival and phase sensitivity of the cell cycle of HeLa cells was studied. In survival experiments no cells survived when the drug was added and left in contact with the cells at or above a dose of 0.7 mug/ml. Cells synchronized by the mitotic-selection method showed changing sensitivity to the drug during the cell cycle. G, late-S, and M phases were more sensitive to dianhydrogalactitol than the early-S and G phases. The DNA synthetic phase was divided into an early low sensitive and a late highly sensitive stage. The different sensitivity of mid-G and early-S phases was further established in separate survival experiments. Cells treated in G phase entered M phase in a manner similar to untreated control cells, while the progress of cells in S or G phase during treatment was delayed significantly. Lack of phase specificity of this drug is consistent with that of other alkylating agents. Changing sensitivity during some phases of the cell cycle proves that some metabolic events are especially sensitive to this particular drug.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1203879

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN: 0069-0112


  3 in total

1.  Dominance of resistance to the alkylating agent 1,2:5,6-dianhydrogalactitol in P388 mouse lymphoma hybrid cells.

Authors:  I Pályi; J Bence; K Szikla; L Hullán
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 2.  New cancer chemotherapy drugs in Europe.

Authors:  G Mathé; L M van Putten
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

3.  Alkylation by 1,2:5,6-dianhydrogalactitol of deoxyribonucleic acid and guanosine.

Authors:  E Institóris; J Tamás
Journal:  Biochem J       Date:  1980-03-01       Impact factor: 3.857

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.